Articles tagged with Prostate Cancer
Researchers have identified a functional DNA element associated with prostate cancer risk, revealing new insights into the molecular mechanisms of the disease. The study found that variants in this region can alter the expression of critical genes, increasing disease risk.
A genetic variant associated with increased expression of oncogene MYC has been identified in a gene desert, increasing prostate cancer risk. The study showcases a new protocol for studying cancer-risk variants in gene deserts and highlights the importance of regulatory sequences in controlling gene expression.
Researchers found that men with a baseline PSA of less than 4 had a very low risk of death from prostate cancer, while those with scores of 10 or higher were 11 times more likely to die. The study suggests routine screening among healthy men with normal life expectancy can help identify high-risk patients and save lives.
A recent study by UNC researchers provides evidence that a specific gene, MAGE-11, interacts with proteins to promote androgen receptor activity in advanced prostate cancer cells. This finding opens the door to additional targets for new therapies and broader clinical applications of new drugs.
Researchers developed a groundbreaking laboratory model of hormone-induced human prostate cancer initiation and progression, offering new insights into the disease's hormonal mechanisms. The model enables the study of cancer development from normal tissue to initiation and progression, facilitating preventive therapy testing and accele...
A 14-year randomized controlled trial shows that prostate cancer screening significantly reduces mortality rates. The study found that men screened for prostate-specific antigen (PSA) had a lower risk of dying from prostate cancer compared to those not screened.
A comprehensive genomic analysis of prostate cancer has identified key alterations in the androgen receptor pathway and defined subsets of low- and high-risk disease. The study provides valuable resources for cancer research and may lead to the creation of a genetic-based test to determine which tumors require aggressive treatment.
Researchers found that optimal brachytherapy dose on the same day as implant reduces relapse risk by 20 percentage points, achieving cure in 94.4% of patients. Calculating radiation dose on implant day allows for immediate adjustments to ensure treatment efficacy.
Researchers found significant association between chlordecone exposure and prostate cancer risk, with higher risk seen in individuals with family history or exposure to Western lifestyle. Genetic susceptibility factors may play a role in this relationship.
A new study found that active surveillance is a suitable treatment option for patients with low-risk prostate cancer, resulting in lower mortality rates compared to radical prostatectomy or radiation therapy. After a median follow-up of 8.2 years, the surveillance group had a higher percentage of deaths from competing causes.
Researchers found that polyphenols in red wine and green tea inhibit cancer growth by disrupting the sphingosine kinase-1 survival pathway. This discovery could lead to the development of drugs targeting this pathway to stop or slow prostate cancer progression, improving current treatments.
Physician-scientists from NewYork-Presbyterian Hospital/Weill Cornell Medical Center present several studies at the 2010 American Urological Meeting, including a potential breakthrough in using 5-alpha reductase inhibitors to improve PSA test accuracy for prostate cancer diagnosis. Additionally, they present results on robotic surgery ...
A new ultrasensitive PSA test using nanoparticle technology can detect low levels of PSA in the blood that indicate cancer recurrence. The test may provide early and more accurate answers, allowing doctors to act at the earliest and most sensitive time for patients' long-term survival.
Researchers found thymoquinone induces oxidative stress in prostate cancer cells, leading to increased cell death and decreased tumor growth. The study suggests a new potential treatment option for highly aggressive prostate cancers.
A study published in Cancer Research found that high calcium intake, even from non-dairy sources such as soy and green vegetables, may increase prostate cancer risk in Chinese men. The research, which analyzed data from over 27,000 men, showed a 25% increased risk of prostate cancer among those consuming higher amounts of calcium.
Men who choose radiotherapy over surgery for prostate cancer have a 17% improvement in overall survival rate, with patients refusing treatment having a 51% 10-year survival rate. This study highlights the importance of considering treatment options when diagnosed with prostate cancer.
The REDUCE trial found dutasteride to be effective in reducing the chance of a positive biopsy by 23% and preventing disease progression. However, more detailed analyses are needed to monitor long-term effects on cardiovascular health and selectively identify aggressive disease.
A recent study by S. Eggener et al. discusses the significance and impact of focal therapy for low-risk prostate cancer patients, highlighting its potential as an alternative to whole-gland treatment. The study reviews patient selection criteria, diagnostic imaging, biopsy schemes, and treatment modalities available for focal therapy.
A new study found that gene fusions are a specific 'bad actor' in prostate cancer and should be targeted by treatments, rather than the androgen receptor. The research suggests that blocking these fusions can prevent normal prostate cell development, allowing cancer to develop.
A new study by researchers found that measuring bone density before starting ADT can help prevent fractures and reduce costs. Another study suggests that CTCA can identify patients who need more invasive testing for heart disease.
A study found that preoperative MRI can help surgeons identify the neurovascular bundle and spare it during RALP, leading to better erectile function outcomes. The technique has improved surgical decision-making without compromising oncological results.
A new study examines the safety and tolerance of SE5-OH containing Natural S-equol in healthy adult Japanese men, with results showing normal hormone levels and PSA levels. The supplement appears to be well-tolerated, but further studies are needed to confirm its effects on prostate health.
Researchers found that men with multiple affected relatives have a substantially increased risk of developing prostate cancer. The study suggests that doctors should urgently recommend early detection screenings for men with several affected relatives, particularly if they have been diagnosed at a young age.
The EAU Congress ended its 25th anniversary meeting in Barcelona with awards for outstanding research in urology. Despite volcanic eruptions disrupting travel plans, the congress proceeded and recognized excellence in cancer and non-cancer research.
Researchers found strong correlation between colder weather, low rainfall, and higher prostate cancer rates in the US. The study suggests that persistent organic pollutants may be to blame, with cold weather slowing their degradation.
A new study suggests that high estrogen levels in men may increase their risk of developing prostate cancer. However, the researchers also found that certain estrogen metabolites may offer a protective benefit against prostate cancer development.
A blood test and DNA analysis accurately predict which men with low-grade prostate cancers may need treatment, say Johns Hopkins scientists. The prostate health index and DNA content in biopsy tissue can detect the progression of small prostate cancers.
A recent study published in Johns Hopkins Medicine found that men who gained five or more pounds near the time of their prostate surgery are twice as likely to have a recurrence of their cancer compared with patients whose weight is stable. Physical activity was shown to reduce this risk.
Researchers have evaluated a blood test that identifies patients with low-grade, low-stage prostate cancer who are at risk of needing treatment. The study found that a biomarker called Prostate Health Index was significant in predicting unfavorable biopsy conversion.
The study demonstrates a potential new treatment paradigm in oncology with improved overall survival rates for metastatic castration-resistant prostate cancer patients. The treatment, Sipuleucel-T, was shown to have well-balanced prognostic factors and mild adverse events.
The European Association of Urology does not recommend mass screening for prostate cancer in Europe, citing the risk of overdiagnosis and overtreatment. Men should be properly informed by their physician about the pros and cons of screening, such as a PSA test.
The European Association of Urology (EAU) has launched new and updated clinical guidelines for urological conditions, including muscle-invasive and metastatic bladder cancer and prostate cancer. The guidelines provide evidence-based recommendations on diagnosis, staging, treatment options, and follow-up care.
A new multicenter study has found that MDV3100 is safe and effective for patients with castration-resistant prostate cancer. The drug slowed tumor growth, reduced PSA levels, and stabilized disease progression, offering new hope for patients with limited treatment options.
A study published in The Lancet Oncology found that men with prostate cancer are at increased risk of potentially life-threatening blood clots. Patients receiving endocrine therapy had the highest risk, especially younger men and those with advanced disease.
Researchers at Emory University have successfully developed a clinical test for XMRV, a retrovirus linked to prostate cancer, using neutralizing antibody assay technology. The test has been confirmed by two independent labs and technologies, providing confidence in its accuracy.
A new study found that certain HIV drugs can inhibit a retrovirus linked to prostate cancer and chronic fatigue syndrome. Raltegravir and other antiviral medications showed effective virus replication inhibition, suggesting possible treatments for these devastating illnesses.
Researchers found that four HIV anti-drugs inhibit XMRV replication, potentially offering a new treatment for prostate cancer and chronic fatigue syndrome. Combination therapies may also delay or prevent the virus from mutating into drug-resistant forms.
A four-year international trial found that dutasteride reduced the chances of being diagnosed with mid-range aggressiveness tumors, which account for most prostate cancers. The drug was effective at reducing the risk of medium-grade tumors by 31.4% in men with a family history of prostate cancer.
A study by UC Davis researchers found that consuming walnuts can significantly slow prostate cancer growth in mice. The walnut diet resulted in smaller tumors and reduced levels of the protein IGF-1, which is associated with prostate cancer.
A study found that walnuts reduced the size and growth rate of prostate cancer in test animals by 50% and 30% respectively. The scientists attributed this effect to walnuts' ability to lower levels of insulin-like growth factor-1 and endothelin, a substance linked to inflammation.
A new study published in Cancer suggests that infertile men are 2.6 times more likely to be diagnosed with high-grade prostate cancer than fertile men. The research found no association between the number of children a man has and his risk for prostate cancer, but rather focused on male fertility as a potential risk factor.
Researchers have discovered that pre-treating mice with noscapine before injecting them with prostate cancer cells resulted in tumor growth rates being two-thirds smaller and lung metastasis rates being 80% less. The study suggests that noscapine may offer significant benefits in the management of prostate cancer as a preventive measure.
A study found that increasing the radiation dose for prostate cancer treatment did not lead to increased long-term side effects. Patients reported minimal distress from chronic symptoms, with many considering their quality of life 'normal' despite experiencing symptoms. The results suggest that patients may adapt to treatment and exper...
Magnetic resonance-guided focal therapy offers a new treatment choice for patients with recurrent prostate cancer, providing an alternative to radiation therapy and hormone manipulation. The procedure involves tailored treatment modality and duration based on lesion size and location, preserving sexual and urinary function.
Researchers at Van Andel Institute developed a new model to study prostate cancer, finding that normal secretory cells depend on E-cadherin binding for survival, unlike cancer cells which rely on androgen. This discovery could lead to therapies targeting tumor cells without harming normal cells.
African-American men have a higher incidence and death rate from prostate cancer, with the highest mortality rate of any racial or ethnic group. A new study found an inheritable genetic defect in the receptor for male hormone testosterone that may contribute to its development.
Researchers have detected a novel oncolytic viral therapy against prostate cancer using the reovirus, showing safety and efficacy in early-stage patients. The study found that the virus induced cancer cell death without replicating in normal tissues, with minimal toxicity reported.
A new study shows that robotic-assisted laparoscopic prostatectomy (RALP) does not compromise surgical outcomes for patients with prostate cancer. Surgeons can use visual cues to improve clinical outcomes, including the color of tissue, vein locations, and signs of inflammation.
Monash University scientists have identified a new way to treat castrate-resistant prostate cancer cells using estrogen receptors. The study shows that activating these receptors can cause cell death in patients with advanced prostate cancer.
A new study published in The Journal of Urology found that open radical prostatectomy (ORP) and laparoscopic radical prostatectomy (LRP) have similar rates of postoperative mortality and morbidity. LRP was associated with shorter hospital stays and a lower risk of bladder neck or urethral obstruction.
US PSA screening detected fewer prostate cancers compared to a European randomized trial, with lower sensitivity being the main cause. The estimated sensitivity of PSA testing followed by biopsy was significantly lower in the US (0.26) than in the European trial (0.94).
Queen's University researchers discovered a low-dose nitroglycerin treatment may slow and halt prostate cancer disease progression without severe side effects. The study, which targeted 29 men with increasing PSA levels following surgery or radiation, showed significant slowing in disease progression in all but one patient.
Researchers found that prostate cancer cells can lose the DAB2IP protein, which acts as scaffolding to prevent cell growth, allowing them to break free and spread to other parts of the body. The study suggests that restoring this function could inhibit cancer progression.
A new study found that men diagnosed with prostate cancer in the US face a higher risk of suicide and cardiovascular death, particularly during the first year after diagnosis. The study suggests that providing emotional counseling and support for patients newly diagnosed with cancer may be essential to mitigate this risk.
Researchers used MR spectroscopy to analyze the biochemical makeup of prostate glands and accurately identified the location of tissue confirmed to be malignant. The approach achieved an accuracy of over 90% in detecting stage II tumors and could potentially guide treatment planning.
A study published in the journal Cancer found that prostate cancer treatment decisions are influenced by the type of healthcare facility where patients receive care. Patients treated in county hospitals are more likely to undergo surgery, while those in private facilities tend to receive radiation or hormone therapy.
A clinical trial shows that patients with metastatic prostate cancer who received a vaccine lived substantially longer than those who received a placebo, with a median survival time of 24.5 months compared to 16 months. The study found encouraging evidence for a clinically meaningful benefit from this vaccine approach.
A new study from Duke University Medical Center found that diabetes negatively affects prostate cancer outcomes in obese white men following radical prostatectomy. However, the impact of diabetes on prostate cancer progression varies by race and weight, with lower risks observed in other subgroups.
Researchers have discovered a genetic variant associated with aggressive prostate cancer, which may help identify men at risk of developing the disease. The study found that this genetic marker was present in 25% more men with aggressive disease than those with slow-growing disease.
Researchers found TRAP-1 to be highly expressed in prostate cancer cells, inhibiting cell death, while Gamitrinib treatment killed cancer cells but not healthy ones. This suggests targeting TRAP-1 may provide a new approach for treating advanced prostate cancer.